Krueger v. Wyeth Inc

District Court, S.D. California·Decided October 1, 2019·No. 3:03-cv-02496·Unknown

Opinion

APRIL KRUEGER, individually and on Case No.: 3:03-cv-2496-JAH (MDD) behalf of all others similarly situated, ORDER OVERRULING Plaintiff, DEFENDANTS’ OBJECTIONS v. [DOC. NO. 330] WYETH, INC. f/k/a AMERICAN HOME PRODUCTS, a Pennsylvania corporation; WYETH PHARMACEUTICALS f/k/a WYETH-AYERST PHARMACEUTICALS, a Pennsylvania corporation; and DOES 1 through 100 Inclusive, Defendants. INTRODUCTION Defendants Wyeth, Inc., and Wyeth Pharmaceuticals (“Defendants”) filed a motion to amend the scheduling order to reopen discovery and for permission to conduct discovery of a sampling of absent class members and prescribers. Doc. No. 305. Magistrate Judge Dembin denied the discovery motion and Defendants filed an objection. Doc. No. 323, 330. After initial and supplemental briefing, Defendants’ objection is now before the Court. For the reasons set forth below, the Court OVERRULES Defendants’ objections. This consumer protection class-action lawsuit was filed in 2003. Doc. No. 1. The case was transferred to a Multi-District Litigation (“MDL”) pending in the Eastern District of Arkansas. Doc. No. 6. After limited discovery and motions practice, this action was remanded to this District from the MDL in 2007. Doc. No. 9. On March 30, 2011, this Court granted in part and denied in part Plaintiff’s class certification motion, doc. no. 108, and certified the following Class: All California consumers who purchased Wyeth’s Hormone Replacement Therapy products, Premarin, Prempro, and/or Premphase, for personal consumption between January 1995 and January 2003, and were exposed to a representation from Wyeth, or health care providers, or read in literature in which Wyeth advertised or provided to third parties to be disseminated under its brand or the third parties’ brand, that Premarin, Prempro, and/or Premphase lowered cardiovascular, Alzheimers and/or dementia risk, or did not increase breast cancer risk, and do not seek personal injury damages resulting therefrom. (emphasis added). Defendants objected to the inclusion of the exposure criteria in the class definition by filing their Motion for Reconsideration of the Class Certification Order. Doc. No. 110-1 at 2. Defendants argued that “[a]scertaining who falls within this definition would require individualized inquiries of each potential class member to determine whether she saw any of [the] numerous representations regarding HT and, if so, when.” Id. at 5. On July 13, 2011, Defendants’ motion for reconsideration of the Order granting class certification was denied. Doc. No. 122. Defendants filed a petition for permission to appeal the Order certifying the class and the Order denying the motion for reconsideration. The Ninth Circuit denied the petition on October 18, 2011. A month later, the parties filed the Joint Discovery Plan in which the Defendants stated that they planned “to pursue discovery on a number of matters, including, but not limited to: (3) Class members’ physicians’ views regarding Premarin, Prempro and Premphrase; (4) Class members’ exposure to written or oral statements regarding the potential benefits or risks of Premarin, Prempro and Premphrase; (5) Class members’ knowledge regarding the potential benefits or risks of Premarin, Prempro and Premphrase. Doc. No. 126 at 4. The discovery phase began on November 30, 2011 and was scheduled to close on June 15, 2012 pursuant to the scheduling order. Doc. Nos. 152, 130. On May 8, 2012, the parties filed a joint motion for a determination of a discovery dispute. Doc. No. 158. The dispute involved the scheduling of nine depositions of non- party witnesses, all of whom were former employees of Defendants. Id. Counsel for the witnesses sought a six-week extension through August 3, 2012. Id. The magistrate judge found good cause to extend the fact discovery deadline to July 20, 2012, “for the sole purpose of taking the depositions of the nine persons identified in the joint motion.” Doc. No. 159. At that time, the magistrate judge ruled: No other fact discovery is authorized beyond June 15, 2012. To the extent that any of these depositions would cause Plaintiff to exceed the ten-deposition limit of Rule 30, Plaintiff must obtain a stipulation from Defendants or seek leave of Court as required. (emphasis added). Id. at 2 On May 16, 2012, Plaintiff filed a motion for leave to take fourteen additional depositions. Doc. No. 160. Defendants opposed Plaintiff’s motion but offered to stipulate to five additional depositions. See Doc. No. 162. The magistrate judge found that Defendants’ proffered stipulation was reasonable and allowed Plaintiff a total of fifteen depositions. Doc. No. 163 at 3. However, the court emphasized that discovery deadlines would remain unchanged; with a fact discovery deadline of July 20, 2012 and an expert discovery deadline of August 10, 2012. Id. At the conclusion of discovery and after denying Defendants’ initial motions for summary judgment and to decertify the class, this Court invited both parties to file supplemental briefs addressing whether to amend the class definition considering the issue of ascertainability. Doc. No. 274 at 2. In the October 7, 2015 Order on the supplemental briefs, this Court deleted the exposure requirement from the class definition, doc. no. 295, concluding that it is not necessary to reference exposure in the class definition where, as here, the Court had already drawn the certification-stage class-wide inference of reliance. In doing so, the Court found that there was sufficient evidence that Defendants employed a massive, systematic advertising campaign during the class period for a fact-finder to conclude that HRT users and prescribing physicians were exposed to the alleged misrepresentations. The Court adopted Plaintiff’s suggested class definition and amended the definition to include: All California consumers who purchased Wyeth’s Hormone Replacement Therapy products, Premarin, Prempro, and/or Premphase, or personal consumption between January 1995 and January 2003, and who do not seek personal injury damages resulting therefrom. A case management conference was held on December 11, 2015 and the magistrate judge set a briefing schedule on Defendant’s request for discovery of absentee class members. Doc. No. 304. On January 8, 2016, Defendants filed the motion seeking to amend the scheduling order and for absent class member discovery. Doc. No. 305. The motion was fully briefed by the parties. See Doc. Nos. 306, 308, 312. Defendants argued “the removal of the exposure requirement dramatically changed the class definition, and the Court imposed a presumption of exposure that did not exist before.” Doc. No. 312. Defendants sought permission to conduct limited surveys and depositions from a sampling of absent class members and their prescribers to determine: (1) whether absent class members were exposed to the alleged misrepresentations, (2) the degree of exposure, and (3) the effect of that exposure on individual class members’ decisions to purchase the hormone therapy medication. Id. at 25. In addition, Defendants argued that discovery is highly relevant, and necessary to present their defense that individual class members cannot prove an injury or harm if they were not exposed to any alleged misrepresentation – elements required for both Article III standing and liability under California consumer protection laws. Doc. No. 305-1 at 8. On April 4, 2016, the magistrate judge issued an order denying Defendants’ motion to reopen discovery. The magistrate judge found: Defendants… failed to show good cause for amending the Scheduling Order…[T]he 2015 Order did not shift the burden of proof to Defendants on any elements or Article III standing, nor did it enlarge the Class in any way that deprives Defendants of the right to present any defense. Further, Defendants have not shown good cause because they were aware of the facts and theories supporting their request for discovery of absent class members’ expos

Free access — add to your briefcase to read the full text and ask questions with AI

Krueger v. Wyeth Inc, (S.D. Cal. 2019).

Krueger v. Wyeth Inc (Krueger v. Wyeth Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Affiliated Ute Citizens of Utah v. United States
406 U.S. 128 (Supreme Court, 1972)
Francis v. Franklin
471 U.S. 307 (Supreme Court, 1985)
Stearns v. Ticketmaster Corp.
655 F.3d 1013 (Ninth Circuit, 2011)
Mazza v. American Honda Motor Co., Inc.
666 F.3d 581 (Ninth Circuit, 2012)
Vasquez v. Superior Court
484 P.2d 964 (California Supreme Court, 1971)
In Re Tobacco II Cases
207 P.3d 20 (California Supreme Court, 2009)
Steroid Hormone Product Cases
181 Cal. App. 4th 145 (California Court of Appeal, 2010)
Daro v. Superior Court
61 Cal. Rptr. 3d 716 (California Court of Appeal, 2007)
Pfizer Inc. v. Superior Court
182 Cal. App. 4th 622 (California Court of Appeal, 2010)
Massachusetts Mutual Life Insurance v. Superior Court
119 Cal. Rptr. 2d 190 (California Court of Appeal, 2002)
Nwachukwu v. Jackson
50 F. Supp. 2d 18 (District of Columbia, 1999)
DeFazio v. Wallis
459 F. Supp. 2d 159 (E.D. New York, 2006)
Anunziato v. eMachines, Inc.
402 F. Supp. 2d 1133 (C.D. California, 2005)
Jadwin v. County of Kern
767 F. Supp. 2d 1069 (E.D. California, 2011)
Benjamin Berger v. Home Depot U.S.A., Inc.
741 F.3d 1061 (Ninth Circuit, 2014)
Frost v. City of Los Angeles
183 P. 342 (California Supreme Court, 1919)
Bacilio Ruiz Torres v. Mercer Canyons Inc.
835 F.3d 1125 (Ninth Circuit, 2016)